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INTRODUCTION
Exercise-induced bronchoconstriction (EIB) is associated with 
vigorous physical exertion in 45%-85% of children with asthma.1 
EIB is a highly prevalent but discrete clinical phenotype that 
shares common features with other measures of indirect bron-
chial hyperresponsiveness (BHR).2 The presence of EIB as a dis-
tinct pathophysiology in children may precede the develop-
ment of other features of asthma, representing an early stage of 
the disease.3
Exercise causes asthma attacks due to the loss of water from 
the surface of the airways by evaporation when inspired air is 
exposed to conditions inside the body.4 This loss of water in-
creases airway osmolarity, which initiates the activation of epi-
thelial and mast cells and releases inflammatory mediators into 
the airways, leading to bronchoconstriction.5-8 The pathogene-
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sis of EIB involves the release of cysteinyl leukotrienes (CysLTs), 
demonstrated by the release of CysLTs into the airways,9,10 an 
increase in leukotriene E4 (LTE4; a marker of CysLTs production 
and elimination) in the urine,11 and the inhibition of EIB phar-
macologically by drugs that antagonize CysLTs.12
Clinicians currently have two main options for the initiation 
of pharmacotherapy in children with mild-to-moderate persis-
tent asthma. These include inhaled corticosteroids (ICSs) or 
leukotriene modifiers such as montelukast. Regular antiasthma 
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Purpose:  This study assessed the association between the ratio of leukotriene E4 (LTE4) to fractional exhaled nitric oxide (FENO) in the response of 
children with exercise-induced bronchoconstriction (EIB) enrolled in a therapeutic trial with montelukast or inhaled corticosteroid (fluticasone propio-
nate [FP]).  Methods:  Children aged 6 to 18 years with EIB were randomized in a 4-week, placebo-controlled, double-blinded trial with montelukast 
or FP. Before and after treatment, treadmill exercise challenges were performed. The LTE4 levels in the induced sputum and urine and the FENO levels 
were measured in subjects before and 30 minutes after the exercise challenges. The same tests were conducted after treatment.  Results:  A total 
of 24 patients completed the study: 12 in the montelukast group and 12 in FP group. Both study groups displayed a similar postexercise maximum 
decrease in forced expiratory volume in one second (FEV1) before treatment as well as after treatment. However, there were significant differences 
in the magnitude of change between the two (Δ; -18.38±14.53% vs. -4.67±8.12% for the montelukast and FP groups, respectively; P=0.021). The 
Δ logarithmic sputum baseline and postexercise LTE4/FENO ratio were significantly lower in the montelukast group than in the FP group (baseline; 
-0.09±0.21 vs. -0.024±0.03, P=0.045; postexercise, -0.61±0.33 vs. -0.11±0.28, P=0.023).  Conclusions:  These data indicate that the efficacy 
of montelukast for preventing a maximum decrease in FEV1 after exercise is significantly higher than that of FP, and the high LTE4/FENO ratio is asso-
ciated with a greater response to montelukast than to FP for EIB therapy. These results suggest that LTE4 may play an important role in EIB.
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treatments with ICSs and leukotriene modifiers alleviate EIB.13-15 
Clinical trials have shown that ICSs improve asthma control 
more effectively in both children and adults than leukotriene 
modifiers.16 However, there is a subset of patients who appear 
to respond better to leukotriene modifiers with greater improve-
ment in lung function and asthma control.17-19 Two recent stud-
ies suggested that high LTE4 levels relative to fractional exhaled 
nitric oxide (FENO) were associated with a better response to 
montelukast compared to ICS therapy in the attenuation of alb-
uterol usage20 and a greater forced expiratory volume in one 
second (FEV1).19
FENO and urinary LTE4 have been used as noninvasive mark-
ers of airway inflammation in children with asthma.21-23 The in-
volvement of CysLT and eosinophilic inflammation can be mea-
sured by urinary LTE4 and FENO, respectively. In the present 
study, we investigated the association between the ratio of LTE4 
to FENO and the response of therapeutic trials with montelukast 
or inhaled corticosteroids (fluticasone propionate [FP]) in asth-
matic children with EIB.
MATERIALS AND METHODS
Subjects
Subjects were recruited from outpatient clinics of Hanyang 
University Hospital and screened with an exercise broncho-
provocation test under an approved study protocol by the Han-
yang University Hospital Institutional Review Board. All sub-
jects provided written informed consent. The study participants 
consisted of 24 children with asthma between the ages of 6 and 
18 years. Participants with ≥15% postexercise maximum de-
crease in FEV1 were enrolled. Asthma was defined as the pres-
ence of symptoms, either an increased FEV1≥12% after bron-
chodilator treatment, or ≤16.0 mg/mL, if inhaled methacho-
line induced a 20% decrease in FEV1.24 The classification of 
asthma severity was based on the guidelines of the Global Ini-
tiative for Asthma using an algorithm including the medication 
dose and adherence, FEV1, and the symptom levels.25 Asthma 
was stable in all asthmatic patients at the time of the study. The 
exclusion criteria included acute exacerbation of asthma with-
in the previous 6 months and parenchymal lung disease appar-
ent on chest radiography within 4 weeks. Participants were ex-
cluded if they had used an ICS, leukotriene modifier, long-act-
ing antihistamine, or long-acting β2-agonist 30 days before the 
study, and those with an FEV1 below 70% of the predicted val-
ues were also disqualified. Skin prick tests (SPTs) for common 
inhalant and food allergens including Dermatophagoides fari-
nae, D. pteronyssinus, cat dander, dog dander, Alternaria alter-
nata, cow milk, egg white, peanut, wheat, and soybean (Aller-
gopharma, Reinbek, Germany), together with negative (saline) 
and positive (histamine) controls, were performed. A positive 
response was defined as a mean wheal diameter equal to or 
greater than one-half of the positive control. Specific IgE against 
the same common allergens that were used in the SPTs were 
measured with the Immuno-CAP system (Phadia AB, Uppsala, 
Sweden). For this analysis, atopy was defined as the presence of 
at least one positive allergen-specific IgE test result (IgE≥0.35 
kU/L) or SPT finding. The spirometry, methacholine, and exer-
cise challenge tests were performed by a trained technician.
Study protocol
This study was a randomized, double-blind, placebo-con-
trolled trial comparing the effects of FP to those of montelukast 
in children with EIB. Children were randomized to receive ei-
ther 5 or 10 mg montelukast (Singulair®; Merck/MSD, White-
house Station, NJ, USA) with a fluticasone placebo (from train-
ing diskus) or fluticasone (Seretide® diskus; GlaxoSmithKline, 
London, UK) with a montelukast placebo for a 4-week period. 
The participants had a total of four visits. Two studies were per-
formed prior to treatment at baseline and 30 minutes after ex-
ercise challenge on separate days (4-day interval). Two studies 
were performed after treatment at baseline and 30 minutes af-
ter exercise challenge on separate days (4-day intervals). Blood 
tests were performed for the measurement of eosinophils, serum 
IgE, eosinophilic cationic protein (ECP), and cytokines. FENO-
induced sputum was used to measure LTE4, cytokines, eosino-
phils, and ECP. Urine was used to measure LTE4. Samples were 
collected at baseline and 30 minutes after exercise challenge on 
separate days during a 4-day characterization period prior to 
treatment. Children were treated for 4 weeks. Following treat-
ment, blood, FENO-induced sputum, and urine were collected 
at baseline and 30 minutes after exercise challenge on separate 
days during a 4-day characterization period following treat-
ment.
Spirometry and methacholine challenge
Spirometry and methacholine challenges were conducted in 
accordance with the American Thoracic Society guidelines.24 
Spirometry was performed with a Masterlab® spirometer (Jae-
ger Co., Freiburg, Germany).26 The bronchodilator response 
was calculated as the percentage change in FEV1 from baseline 
15 minutes after inhaling 0.2 mg salbutamol sulfate (Ventolin®; 
GlaxoSmithKline) via a metered dose inhaler. Methacholine 
challenges were performed using a modified Chai procedure.26
Exercise challenge
Exercise challenges were conducted in accordance with the 
American Thoracic Society guidelines.24 An exercise challenge 
test was performed by running with the nose clipped on a tread-
mill (LE 200 CE; Jaeger Co., Hoechberg, Germany) using a stan-
dardized protocol. During the test, the heart rate was continu-
ously monitored by a radiographic device (electronic electro-
cardiogram [ECG] monitor, BCI Autocorr). The ambient tem-
perature in the air-conditioned laboratory was kept constant at 
22°C, and the humidity was 40%-50% on each day of the study. 
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The inspired air temperature and humidity were measured. 
The test began with running at a low speed on the treadmill with 
a 10% incline. The running speed of the treadmill was increased, 
raising the heart rate to approximately 85% of the predicted 
maximum [(220-age)×0.9]. This speed was maintained for a 
maximum of 6 minutes. Spirometry was conducted 20 and 5 
minutes prior to each exercise challenge and repeated 0, 3, 6, 
10, 15, and 20 minutes after the end of each exercise event. The 
better test sample of at least two FEV1 maneuvers within 5% of 
each other was recorded at each time point. The area under the 
FEV1-time curve (expressed as the percentage change from 
baseline values) over a 20-min period after exercise (AUC20)12 
was used as an index of the severity of EIB. The AUC20 values 
were calculated using the trapezoidal rule.
Sputum induction
Induced sputum was conducted with 4.5% hypertonic saline 
administered through an ultrasonic nebulizer (DeVilbiss, Som-
erset, PA, USA), as previously described.20 In 2-min intervals, 
the subjects were asked to clear saliva from their mouth and ex-
pectorate sputum. The sputum was collected over 12 minutes 
and pooled into a single sample container. The induced spu-
tum was placed on ice and processed within 30 minutes of col-
lection. Samples were coded with a subject number, visit num-
ber, and date. The link between the clinical characteristics of 
the participants and the coded label was maintained in a sepa-
rate file by the principal investigator. The total and differential 
cell counts were performed by an investigator (MWM) who was 
blinded to the clinical characteristics of each participant. The 
levels of LTE4, ECP, interleukin (IL)-4, IL-5, IL-8, interferon 
(IFN)-γ, and IL-17 were determined in the induced sputum su-
pernatants.
Mediator assays
The concentrations of IL-4, IL-5, IL-8, IFN-γ, and IL-17 in the 
induced sputum and blood were determined using the cytokine 
multiplex assay. Enzyme immunoassay analyses of LTE4 were 
performed in crude urine samples and induced sputum super-
natants using competitive enzyme immunoassays for LTE4 (Cay-
man Chemical Company, Ann Arbor, MI, USA) as described by 
O’Sullivan et al.27 The concentration of each sample was deter-
mined from a standard curve ranging from 7.8 to 1,000 pg/mL. 
The precision of the EIA for LTE428 was 17.6%. The urine LTE4 
levels were reported in picograms and standardized per milli-
gram of creatinine. Urine creatinine analyses were performed 
using a colorimetric assay (Sigma-Aldrich, St. Louis, MO, USA).
Fractional exhaled nitric oxide
FENO levels were measured with a portable nitric oxide analyz-
er (NIOX MINO®; Aerocrine, Solna, Sweden) that provided 
measurements at a 50 mL/sec exhalation flow rate expressed in 
ppb.29 Determinations made with the device were within the 
clinically acceptable range with measurements provided by a 
stationary analyzer according to the guidelines of the American 
Thoracic Society.30
Statistical analyses
 Data analysis was conducted using SPSS software (version 
16.0; SPSS Inc., Chicago, IL, USA). The variables measured on a 
continuous scale are summarized as the mean±standard error 
(SE). To compare mean values, we used parametric Student’s t-
tests, or nonparametric Mann-Whitney U and Wilcoxon signed-
rank tests where needed. The comparisons of categorical vari-
ables were evaluated using a chi-square test or Fisher’s exact 
test.
RESULTS
Characteristics of the study subjects
This study included 24 patients, 12 in the montelukast group 
and 12 in the FP group. Of the 24 subjects with asthma, 8 dis-
played mild intermittent asthma (4 in the montelukast and 4 in 
the FP group), 10 had mild persistent asthma (6 in the monte-
lukast and 4 in FP group), and 4 displayed moderate asthma (2 
in the montelukast and 2 in the FP group). No significant differ-
ences in asthma severity, the mean values of age, sex distribu-
tion, the rates of atopy, or prior use of ICSs between the monte-
lukast and FP groups were observed (Table 1). No significant 
Table 1.  Characteristics of studied children and baseline values
Montelukast 
group (n=12)
FP group 
(n=12)
P value*
Age (yr)  9.29±3.68 10.11±2.61 0.781 
Sex (% male)  63.4  62.6  0.078†
Clinical features 
Atopy (%)  84.2  82.6  0.732‡
Prior ICS use (%) 47.4  43.5  0.801‡
Postexercise maximum decrease 
in FEV1 (%)
21.00±5.36 23.54±4.59 0.564
PC20 (mg/mL) 
Cellular findings from induced 
sputum
6.9±4.8 4.8±2.45 0.417
Eosinophil percentage† 2.11±0.54 1.33±1.26 0.218
Neutrophil percentage† 20.49±5.97 32.25±18.83 0.468
Sputum LTE4 (pg/mL) 347.1±323.4 452.6±281.9 0.287
Urine LTE4 (pg/mL creatinine) 28.1±9.7 29.7±19.7 0.363
FENO (ppb) 27.1±17.3 26.3±17.6 0.879
Serum ECP (ng/mL)  29.7±13.7 33.9±17.1 0.452
Sputum ECP (ng/mL) 29.0±52. 66.3±58.6 0.260
ECP, eosinophil cationic protein; FENO, fractional exhaled nitric oxide; ICS, inhaled 
corticosteroids; PC20 provocative concentration of methacholine inducing a 20% 
decrease in forced expiratory volume in one second (FEV1). Data are presented 
as absolute numbers, mean±standard error (SE), or median (interquartile range). 
*Mann-Whitney U test; †Chi-square test; ‡Fisher’s exact test.
Leukotriene E4/Exhaled Nitric Oxide Ratio
Allergy Asthma Immunol Res. 2013 January;5(1):26-33. http://dx.doi.org/10.4168/aair.2013.5.1.26
AAIR 
29http://e-aair.org
differences were observed in the baseline values of postexercise 
maximum decrease in FEV1 and PC20 (Table 1). No significant 
differences in the induced sputum volume (1.46±0.97 mL vs. 
1.53±1.05 mL, P=0.185) or the concentration of the lower air-
way cells in the induced sputum (1.18±0.98×106 cells/mL vs. 
1.23±1.17×106 cells/mL, P=0.732) were evident between the 
two groups. There were no significant differences in the base-
line values of the percentage of eosinophils and neutrophils be-
tween the montelukast and FP groups (Table 1). No significant 
differences were observed in the baseline levels of sputum LTE4, 
urinary LTE4, FENO, or serum and sputum ECP between the 
groups (Table 1).
Effects of exercise on inflammatory markers
No significant changes were observed in the sputum volume 
and concentration of the lower airway cells in the induced spu-
tum at baseline and after exercise challenge in either group. No 
significant differences were detected in eosinophils, macro-
phages, lymphocytes, and neutrophils in the induced sputum 
between the baseline and post-exercise samples, or between 
the two groups (data not shown). The sputum LTE4 significantly 
increased in the airways after exercise challenge in the monte-
lukast group (347.1±323.4 pg/mL vs. 1,109.5±841.1 pg/mL, P=
0.027) and in the FP group (452.6±281.9 pg/mL vs. 1,447.5±
921.1 pg/mL, P=0.032) compared to those at baseline, while 
the urinary LTE4 did not. The sputum LTE4/FENO significantly 
increased in the airways after exercise challenge in the monte-
lukast group (20.59±15.26 vs. 44.53±39.85, P=0.027) and in 
the FP group (27.37±17.58 vs. 55.73±44.91, P=0.032) compared 
to those at baseline, while the urinary LTE4/FENO did not (Fig. 1). 
The baseline levels of ECP and IFN-γ in the serum and sputum 
did not differ compared to those after exercise challenge. The 
levels of IL-5, IL-10, and IL-17A in the airways and blood were 
below the levels of detection in both groups. No further signifi-
cant differences were observed in the baseline and postexercise 
levels of sputum LTE4, urinary LTE4, serum and sputum ECP 
between the two groups (Table 1).
Treatment effects on the severity of EIB
The postexercise maximum decrease in FEV1 and AUC20 de-
creased significantly following the 4-week treatment in both 
groups, but were significantly lower in the montelukast group 
than in the FP group (8.83±7.74% vs. 16.54±7.71%, P=0.024; 
232.1±187.9 vs. 374.9±145.0, P=0.035; Table 2 and Fig. 2). 
There were significant differences in the magnitude of change 
between the two (Δ; -18.38±14.53% vs. -4.67±8.12% for the 
montelukast and FP groups, respectively; P=0.021; Fig. 3A). 
There were also significant differences in the Δ AUC20 between 
the groups (-21.23±17.53 vs. -3.72±3.81, P=0.028; Fig. 3B).
Effects of treatment on inflammatory markers during EIB
There were no significant differences in the percentage of eo-
sinophils between treatments in the montelukast group (base-
line, 2.11±0.54 vs. 1.34±0.41, P=0.077; postexercise, 2.05±2.59 
vs. 2.19±0.82, P=0.643) or the FP group (baseline, 2.11±0.54 
vs. 1.34±0.41, P=0.062; postexercise, 2.05±2.59 vs. 2.19±0.82, 
P=0.647). There were no significant differences in the percent-
age and concentrations of macrophages, lymphocytes, and 
neutrophils at baseline and postexercise between treatments 
(data not shown). A significant decrease in the levels of sputum 
LTE4 at baseline and postexercise after treatment compared to 
those before treatment was observed in the montelukast group 
Fig. 1. Sputum and urinary LTE4/FENO, baseline and postexercise, before and after treatment in the 
two study groups of asthma. There were significant differences in the sputum LTE4/FENO ratio at base-
line and postexercise after treatment compared to those before treatment in the montelukast group 
(baseline, 25.66±23.47 vs. 8.42±8.01, P=0.008; postexercise, 45.72±52.94 vs. 16.63±15.26, P=
0.001) (A) and in the FP group (baseline, 25.24±17.58 vs. 20.41±17.54, P=0.048; postexercise, 
51.10±47.91 vs. 45.79±39.86, P=0.044) (B). There were significant differences in the urine LTE4/FENO 
ratio at baseline and postexercise between treatments in the montelukast group (baseline, 2.36±2.37 
vs. 0.88±0.38, P=0.012; postexercise, 2.53±1.64 vs. 1.04±0.68) (C) and in the FP group (baseline, 
2.23±2.01 vs. 1.60±1.48, P=0.038; postexercise, 2.28±1.75 vs. 1.71±1.39, P=0.043) (D).
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Table 2.  Postexercise maximum decrease in FEV1 and AUC20 before and after treatment in the two study groups of asthmatic children
Montelukast group (n=12) FP group (n=12)
Before treatment After treatment Before treatment After treatment
Postexercise maximum decrease in FEV1 (%) 21.00±5.36 8.83±7.74*† 23.54±4.59 16.54±7.71*
AUC20 (percentage change×min) 503.4±117.8 232.1±187.9* 527.7±88.5 374.9±145.0*
Data are expressed as the mean±SE. *P<0.05 compared to before treatment, analyzed using a Wilcoxon singed-rank test. †P<0.05 compared to FP group, ana-
lyzed using a Mann-Whitney U test.
Fig. 2.  Mean±SE changes in percent decrease FEV1 after exercise challenge before treatment (A) and after 4 weeks of asthma treatment (B) with montelukast 
(n=12) or FP (n=12). No significant differences were observed in the postexercise maximum decrease in FEV1 and area under the FEV1 curve over the first 20 min af-
ter exercise (AUC20) before treatment between two groups (A). Postexercise maximum decrease in FEV1 and AUC20 in the montelukast group were significantly lower 
compared to those of the FP group after treatment (8.83±7.74% vs. 16.54±7.71%, P=0.024; 232.1±187.9 vs. 374.9±145.0, P=0.035) (B).
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Fig. 3. Difference between two measurements after and before treatment for the montelukast and FP groups. There were significant differences in the Δpostexercise 
maximum decrease in FEV1 between the montelukast group and the FP group (-18.38±14.53% vs. -4.67±8.12%, P=0.021) (A). There were significant differences 
in the ΔAUC20 between the montelukast group and the FP group (-21.23±17.53 vs. -3.72±3.81, P=0.028) (B). The Δ logarithmic sputum baseline and postexercise 
LTE4/FENO ratio were significantly lower in the montelukast group compared to the FP group [baseline, -0.09±0.21 vs. -0.024±0.03, P=0.045 (C); postexercise, -0.61±
0.33 vs. -0.11±0.28, P=0.023 (D)]. The Δ logarithmic urinary baseline and postexercise LTE4/FENO ratio were significantly lower in the montelukast group compared 
to the FP group [baseline, -0.60±0.21 vs. -0.084±0.14, P=0.046 (E); postexercise, -0.30±0.25 vs. -0.16±0.16, P=0.038 (F)].
Δ, measurementafter treatment - measurementbefore treatment; FP, fluticasone propionate. *P<0.05 Montelukast vs. FP, analyzed by a Mann-Whitney test.
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(baseline, 347.1±323.4 pg/mL vs. 253.2±199.4 pg/mL, P=0.021; 
postexercise, 1,109.5±841.0 pg/mL vs. 554.5±281.9 pg/mL; 
P=0.018) and the FP group (baseline, 452.6±281.9 pg/mL vs. 
203.1±213.7 pg/mL, P=0.038; postexercise, 1,447.5±921.1 pg/
mL vs. 778.6±689.7 pg/mL, P=0.017), but there were no fur-
ther significant differences in the Δbaseline sputum LTE4 or the 
Δpostexercise sputum LTE4 between the groups. There were no 
significant differences in the levels of urine LTE4 at baseline and 
postexercise after treatment compared to those before treatment 
in either group. The levels of sputum ECP at baseline and postex-
ercise before treatment significantly decreased following treat-
ment in the montelukast group (baseline, 41.28±38.83 ng/mL 
vs. 27.91±16.61 ng/mL, P=0.032; postexercise, 78.68±78.46 ng/
mL vs. 29.38±21.41 ng/mL, P=0.009) and the FP group (base-
line, 86.89±75.23 ng/mL vs. 38.56±24.45 ng/mL, P=0.014; 
postexercise, 87.16±87.73 ng/mL vs. 48.67±59.23 ng/mL, P=
0.047). No significant differences were observed in the Δbaseline 
sputum ECP or the Δpostexercise sputum ECP between the 
groups. There were no significant differences in the levels of se-
rum ECP at baseline and postexercise after treatment compared 
to those before treatment. A significant decrease in the levels of 
FENO at baseline and postexercise after treatment compared to 
those before treatment was observed in both the montelukast 
(baseline, 29.36±21.36 ppb vs. 19.00±9.12 ppb, P=0.037; 
postexercise, 28.09±24.48 ppb vs. 18.17±11.51 ppb, P=0.023) 
and FP groups (baseline, 31.58±24.46 ppb vs. 20.25±17.63 
ppb, P=0.034; postexercise, 28.67±12.78 ppb vs. 18.50±11.37 
ppb, P=0.039). There were no significant differences in the 
Δbaseline levels of FENO or in the Δpostexercise levels of FENO 
between the two treatment groups.
There were significant differences in the sputum LTE4/FENO 
ratio at baseline and postexercise after treatment compared to 
those before treatment in both the montelukast (baseline, 
25.66±23.47 vs. 8.42±8.01, P=0.008; postexercise, 45.72±52.94 
vs. 16.63±15.26, P=0.001) (Fig. 1A) and FP groups (baseline, 
25.24±17.58 vs. 20.41±17.54, P=0.048; postexercise, 51.10±
47.91 vs. 45.79±39.86, P=0.044) (Fig. 1B). There were signifi-
cant differences in the urine LTE4/FENO ratio at baseline and 
postexercise between treatments in both the montelukast (base-
line, 2.36±2.37 vs. 0.88±0.38, P=0.012; postexercise, 2.53±1.64 
vs. 1.04±0.68, Fig. 1C) and FP groups (baseline, 2.23±2.01 vs. 
1.60±1.48, P=0.038; postexercise, 2.28±1.75 vs. 1.71±1.39, P=
0.043) (Fig. 1D).
The Δ logarithmic sputum baseline and postexercise LTE4/
FENO ratio were both significantly lower in the montelukast 
group compared to those in the FP group (baseline, -0.09±0.21 
vs. -0.024±0.03, P=0.045, Fig. 3C; postexercise, -0.61±0.33 vs. 
-0.11±0.28, P=0.023, Fig. 3D), as were the Δ logarithmic urinary 
baseline and postexercise LTE4/FENO ratio (baseline, -0.60±0.21 
vs. -0.084±0.14, P=0.046, Fig. 3E; postexercise, -0.30±0.25 vs. 
-0.16±0.16, P=0.038, Fig. 3F).
DISCUSSION
Comparing the effects of oral montelukast and inhaled FP in 
patients with EIB, the postexercise maximum decrease in FEV1, 
and AUC20 were significantly lower in the montelukast group 
than in the FP group. These results are consistent with a recent 
study by Stelmach et al.,31 who observed that montelukast, in 
combination with budesonide or alone, provided the best pro-
tection against EIB compared to other therapeutic options. No 
differences were seen in the degree of EIB protection between 
the two groups receiving montelukast, suggesting a lack of ad-
ditional effects of budesonide on EIB protection in combina-
tion therapy. Earlier studies reported that montelukast reduced 
the immediate and late phases of bronchoconstriction.32-34
This study was conducted using induced sputum, which pro-
vided a sample from the airways.35 We showed that the levels of 
sputum LTE4 significantly increased in the airways 30 minutes 
after exercise challenge in the montelukast and FP groups. The 
pathogenesis of EIB involves the release of CysLTs as demon-
strated by the release of CysLTs into the airways9,10,36 and the 
pharmacological inhibition of EIB using drugs that antagonize 
CysLTs.12 Hallstrand et al.10 demonstrated that treatment with 
CysLT antagonists reduce the severity of EIB and decrease the 
release of CysLTs into the airways. The overproduction of CysLTs 
may increase the susceptibility to EIB through various pro-in-
flammatory mechanisms, as CysLTs mediate airway smooth 
muscle constriction, mucus release, and increased vascular 
permeability.37 Increased levels of CysLTs may be detected in 
the urine after exercise challenge in subjects with EIB,11,38 but 
this has not been observed in all studies.39 In the present study, 
the baseline urinary LTE4 displayed no significant differences 
compared to the post-exercise urinary LTE4.
Although previous reports have associated eosinophilic airway 
inflammation with the severity of EIB,40 we observed no signifi-
cant differences in the eosinophils in the induced sputum be-
tween the baseline and post-exercise samples, or between the 
two treatment groups. Inflammation in asthma is usually asso-
ciated with eosinophilia, whereas isolated EIB in elite athletes 
seems to be more associated with neutrophilic or mixed-type 
airway inflammation.41-45 Airway eosinophilia may not be es-
sential for the development of EIB.9
We showed that the Δ sputum and urinary LTE4/FENO ratio 
were significantly higher in the montelukast group compared 
to those in the FP group in children with EIB (Fig. 3).
In the montelukast group, a greater improvement in EIB was 
observed following treatment compared to the FP group. Un-
derstanding the pathogenesis of EIB is key to effective treat-
ment. The pathogenesis of EIB involves the release of LTE4.9,10,36 
Thus, treatments that block the activity of LTE4 are logically used 
as effective therapies for controlling EIB.28,46 In addition, FENO 
might be considered a marker of allergen-driven, local eosino-
philic inflammation (readily targeted by ICS therapy). The 
Baek et al.
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mechanisms that trigger EIB seem to involve neutrophilic or 
mixed-type airway inflammation.41-45 This inflammation is not 
consistently associated with BHR and does not respond to in-
haled steroids as is characteristic of asthma.47,48 The results of 
the present study are similar to those of earlier studies that re-
ported an association between LTE4/FENO ratios and greater 
FEV1, and that montelukast led to a better asthma control re-
sponse than ICS therapy.19 Our results are also similar to anoth-
er recent study on children with moderate-to-severe asthma 
who predominantly received ICS therapy, which suggested that 
increased albuterol usage among schoolchildren was associat-
ed with high LTE4 levels, relative to FENO, and was attenuated af-
ter randomization for treatment with montelukast.20
Due to the small sample size, the results of the present study 
have several limitations that must be considered when inter-
preting the data. As this study excluded patients with unstable 
asthma and subjects with frequent or unstable asthma exacer-
bations, we cannot specifically state how our findings relate to 
poor asthma control. Montelukast can provide significant pro-
tection against EIB having an onset within 2 hours following a 
single oral dose,49 whereas ICSs exert a maximum effect after a 
few months. As children were treated for 4 weeks in this study, 
we cannot state that improvement in EIB would extend beyond 
this study period. A greater improvement in EIB and Δ LTE4/
FENO ratio were observed in children with asthma treated with 
montelukast compared to FP. We speculate that LTE4 is a more 
general indicator of the inflammatory response to exercise, 
while the allergic-type triggers eosinophilc inflammation and 
specifically increases the FENO levels.
These data indicate that the LTE4/FENO ratio is associated with 
a greater response to montelukast than FP for EIB therapy. These 
results suggest that LTE4 may play an important role in EIB.
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